Samlyn Capital, LLC Satsuma Pharmaceuticals, Inc. Transaction History

Samlyn Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $63,101 - $119,727	-15,060 Reduced 0.51%	2,929,195 $17.6 Million
Q2 2022 Aug 15, 2022	BUY	$2.59 - $4.3 $386,029 - $640,897	149,046 Added 5.33%	2,944,255 $12.2 Million
Q1 2022 May 16, 2022	BUY	$3.78 - $5.32 $3.88 Million - $5.45 Million	1,025,355 Added 57.93%	2,795,209 $10.6 Million
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $223,216 - $335,630	53,787 Added 3.13%	1,769,854 $7.96 Million
Q3 2021 Nov 15, 2021	BUY	$4.54 - $7.17 $600,088 - $947,716	132,178 Added 8.35%	1,716,067 $8 Million
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $1.69 Million - $2.55 Million	351,495 Added 28.52%	1,583,889 $11.2 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $5.63 Million - $8.85 Million	1,232,394 New	1,232,394 $7.28 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.